Literature DB >> 10918431

Early intervention in post-transplant lymphoproliferative disorders based on Epstein-Barr viral load.

Y Hoshino1, H Kimura, K Kuzushima, T Tsurumi, K Nemoto, A Kikuta, Y Nishiyama, S Kojima, T Matsuyama, T Morishima.   

Abstract

Using a real-time quantitative PCR assay, we identified two patients with EBV-related lymphoproliferative disorders at a very early stage. Both had received an unmanipulated bone marrow transplant with anti-thymocyte globulin for conditioning. To estimate virus-specific immunity, the frequencies of EBV-specific CD8+ T cells were measured using an enzyme-linked immunospot assay. The frequencies of EBV-specific CD8+ T cells of the two were 3.2 and 7.7%, respectively, which had possibly expanded in vivo. After withdrawing the immunosuppressive agents or administering donor lymphocytes transfusion, their symptoms regressed in parallel with the viral load.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10918431     DOI: 10.1038/sj.bmt.1702492

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

Review 1.  Real-time PCR in virology.

Authors:  Ian M Mackay; Katherine E Arden; Andreas Nitsche
Journal:  Nucleic Acids Res       Date:  2002-03-15       Impact factor: 16.971

2.  Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation.

Authors:  Claudio G Brunstein; Daniel J Weisdorf; Todd DeFor; Juliet N Barker; Jakub Tolar; Jo-Anne H van Burik; John E Wagner
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

3.  Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease.

Authors:  Barbara C Gärtner; Hansjörg Schäfer; Katja Marggraff; Günter Eisele; Marco Schäfer; Dagmar Dilloo; Klaus Roemer; Hans-Jürgen Laws; Martina Sester; Urban Sester; Hermann Einsele; Nikolaus Mueller-Lantzsch
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

4.  Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation.

Authors:  Anne H Blaes; Qing Cao; John E Wagner; Jo-Anne H Young; Daniel J Weisdorf; Claudio G Brunstein
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-14       Impact factor: 5.742

5.  Development of real-time PCR assays for the quantitative detection of Epstein-Barr virus and cytomegalovirus, comparison of TaqMan probes, and molecular beacons.

Authors:  Jiska Jebbink; Xin Bai; Beverly Barton Rogers; D Brian Dawson; Richard H Scheuermann; Rana Domiati-Saad
Journal:  J Mol Diagn       Date:  2003-02       Impact factor: 5.568

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.